For example, Caplacizumab, a nanobody against von Willebrand factor, has demonstrated rapid and effective outcomes in treating thrombotic thrombocytopenic purpura with fewer adverse reactions, underscoring the potential of nanobodies in immunotherapy (Scully et al., 2019). This evidence concerns the gene VWF and thrombotic thrombocytopenic purpura.